Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI112 safety and PK in healthy subjects
NCT04511624Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of picankibart in plaque psoriasis (7 cohorts), sponsored by Innovent Biologics. Primary endpoint: Incidence of treatment-emergent adverse events. Started Aug 2020; status: completed.
02
Drugs
picankibart
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04511624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511624.